Elena Santagostino

A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one‐stage clotting and chromogenic substrate assays at clinical haemostasis laboratories

WFH Guidelines for the Management of Hemophilia, 3rd edition

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A

Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis

Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Pharmacokinetics of a novel extended half‐life glyco<scp>PEG</scp>ylated factor <scp>IX</scp>, nonacog beta pegol (N9‐<scp>GP</scp>) in previously treated patients with haemophilia B: results from two phase 3 clinical trials

First report on the safety and efficacy of an extended half‐life glyco<scp>PEG</scp>ylated recombinant <scp>FVIII</scp> for major surgery in severe haemophilia A

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

European retrospective study of real‐life haemophilia treatment

Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4)

Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Factor VIII Products and Inhibitor Development in Severe Hemophilia A

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A

Systematic Review of the Role of FVIII Concentrates in Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A: A 2013 Update

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients